Clinical trials: CBT
Panic Disorder
Org 25935 Versus Placebo as Augmentation to Cognitive-behavioral Therapy to Treat Panic Disorder (P05705)
The purpose of this study is to evaluate the effectiveness of Org 25935 vs. placebo given in combination with cognitive-behavioral therapy (CBT) to reduce the symptoms of panic disorder.
- Trial name
- NCT00725725
- Testing
- Cognitive-behavioral therapy, Org 25935
- Volunteers
- 46 people
- Sponsor
- Merck Sharp & Dohme LLC
Depression, Anxiety
Feasibility and Acceptability of W-GenZD vs CBT-light Teletherapy for Adolescents Seeking Mental Health Services
The primary aim of this study is to determine the feasibility and acceptability of the W-GenZD mobile application among a group of adolescents and who have screened and triaged into low-intensity treatment within the Children's…
- Trial name
- NCT05372913
- Testing
- Woebot for Adolescents (W-GenZD) Mobile Application, CBT-Lite Teletherapy Group
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Woebot Health
Posttraumatic Stress Disorder
MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD
The goal of this clinical trial is to learn if cognitive-behavioral conjoint therapy (CBCT) in combination with MDMA-assisted therapy is safe and effective in people with chronic PTSD and their partners.
- Trial name
- NCT02876172
- Testing
- MDMA, CBCT, Therapy
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Resilient Pharmaceuticals
Schizophrenia
Study of Efficacy of PEAR-004 in Schizophrenia
The purpose of the study was to determine in patients currently being administered antipsychotic pharmacotherapy whether PEAR-004 could further reduce symptoms of schizophrenia as measured by the Positive and Negative Syndrome…
- Trial name
- NCT03751280
- Testing
- PEAR-004
- Where
- 6 sites in United States
- Volunteers
- 112 people
- Sponsor
- Novartis Pharmaceuticals
Opioid-use Disorder
OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder
This is an open-label, randomized, parallel-group multicenter study designed to evaluate the efficacy of the digital therapeutic OXD01 (MODIA) combined with sublingual buprenorphine/naloxone standard of care (SL BUP/NAL SOC)…
- Trial name
- NCT04948307
- Testing
- OXD01 digital therapy, Standard of Care
- Where
- 21 sites in United States
- Volunteers
- 437 people
- Sponsor
- Orexo AB
Depression
A CBT-based Mobile Intervention as First Line Treatment for Adolescent Depression During COVID-19
Over 3 million teenagers in the USA have depression, and rates of depression and suicide are sharply increasing. Teenage depression has far-reaching consequences including impairments in academic and work performance and social…
- Trial name
- NCT04524598
- Testing
- Limbix Spark, Psychoeducation
- Where
- United States
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- Limbix Health, Inc.
Anxiety Depression, Disability Physical
Exploratory Study for Toivoa-001 on Human Factors
The Study will evaluate Rauha as an experimental digital therapeutic for persons with Disabilities suffering from anxiety and/or depression.
- Trial name
- NCT06477913
- Testing
- Rauha
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Toivoa Inc
Pulmonary Fibrosis, Anxiety
Controlled Investigation to Evaluate Impact of dCBT on Psychological Symptom Burden in Adult Subjects With PF
The purpose of the study is to assess efficacy and safety of a digital cognitive behavioural therapy for patients with pulmonary fibrosis on anxiety.
- Trial name
- COMPANION (NCT05330312)
- Testing
- Digital cognitive behavioral therapy
- Where
- 2 sites in United States
- Volunteers
- 119 people
- Sponsor
- Vicore Pharma AB
Tinnitus
Mahana Tinnitus Pilot
The main objective of this prospective, open-label, non-significant risk study is to assess the efficacy and safety of Mahana™ Tinnitus together with care as usual in approximately 250 adults with symptoms of tinnitus.
- Trial name
- NCT05696158
- Testing
- MHNA-003
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Mahana Therapeutics